XML 59 R48.htm IDEA: XBRL DOCUMENT
v3.26.1

Note 9 - License Agreements (Details Textual) - USD ($) $ in Thousands |  |  |  |  |  | 1 Months Ended | 3 Months Ended | 6 Months Ended | 171 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | ---
Feb. 23, 2026 | Feb. 10, 2025 | Jan. 07, 2025 | Jan. 07, 2024 | Jul. 28, 2023 | Feb. 28, 2026 | Jun. 30, 2026 | Jun. 30, 2026 | Mar. 31, 2026 | Jun. 30, 2025 | Jan. 31, 2012
Precision BioSciences, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |
Investment Purchased Balance Shares (in shares) |  |  | 220,712 |  |  |  |  |  |  |  |
License Agreement, Percentage of Premium on Equity Investment | 200.00% |  |  |  |  |  |  |  |  |  |
License Agreement, Share Price, Trading Days (Day) | 30 years |  | 30 days |  |  |  |  |  |  |  |
License Agreement, Payment, Percentage of Weighted Average Share Price |  |  | 200.00% |  |  |  |  |  |  |  |
Precision BioSciences, Inc. [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Investment Purchased Balance Shares (in shares) | 201,504 |  |  | 2,920,816 |  |  |  |  |  |  |
Product [Member] |  |  |  |  |  |  |  |  |  |  |
Accounts Receivable, after Allowance for Credit Loss |  |  |  |  |  |  | $ 29,200 | $ 29,200 |  | $ 16,100 |
L F B License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
License And Collaboration Agreement, Expenses Incurred |  |  |  |  |  |  |  |  | $ 31,000 |  |
Accounts Payable |  |  |  |  |  |  |  |  | $ 0 |  |
Royalty Expense |  |  |  |  |  |  | 24,400 | 45,000 |  |  |
Accrued Royalties |  |  |  |  |  |  | 24,300 | 24,300 |  |  |
L F B License Agreement [Member] | License Agreement Terms [Member] |  |  |  |  |  |  |  |  |  |  |
Finite-Lived Intangible Asset, Useful Life (Year) |  |  |  |  |  |  |  |  |  |  | 15 years
Commercialization Agreement With Neuraxpharm [Member] |  |  |  |  |  |  |  |  |  |  |
License and Collaboration Agreements, One-time, Non-refundable Payment |  |  |  |  | $ 140,000 |  |  | 445,300 |  |  |
Additional Amount Receivable on Achievement of Pre-specified Milestones |  |  |  |  | $ 492,500 |  |  |  |  |  |
Royalty Percentage on Net Product Sales |  |  |  |  | 30.00% |  |  |  |  |  |
Revenues |  |  |  |  |  |  | 3,600 | 6,300 |  |  |
Deferred Revenue |  |  |  |  |  |  | 31,400 | 31,400 |  |  |
Accounts Receivable, after Allowance for Credit Loss |  |  |  |  |  |  | $ 3,600 | $ 3,600 |  |  |
Briumvi Ublituximab [Member] | Product [Member] |  |  |  |  |  |  |  |  |  |  |
Product Sales, Net Related to Performance Obligations |  |  |  |  | $ 12,500 |  |  |  |  |  |
Precision License Agreement [Member] |  |  |  |  |  |  |  |  |  |  |
Additional Amount Receivable on Achievement of Pre-specified Milestones |  |  |  |  |  | $ 286,000 |  |  |  |  |
License Agreement, Amount Paid Upfront | $ 7,500 |  |  | $ 7,500 |  | 7,500 |  |  |  |  |
License Agreement, Amount Paid Upfront, Cash | 5,250 |  |  | 5,250 |  | 5,250 |  |  |  |  |
License Agreement, Amount Paid Upfront, Equity Investment | $ 2,250 |  |  | 2,250 |  | $ 2,250 |  |  |  |  |
License Agreement, Deferred Payment |  |  |  | $ 2,500 |  |  |  |  |  |  |
License Agreement, Percentage of Premium on Equity Investment |  |  |  | 100.00% |  |  |  |  |  |  |
License Agreement, Share Price, Trading Days (Day) |  |  |  | 30 days |  | 30 days |  |  |  |  |
License Agreement, Payment, Percentage of Weighted Average Share Price |  |  |  |  |  | 200.00% |  |  |  |  |
Term After First Commercial Sale (Year) |  |  |  |  |  | 10 years |  |  |  |  |
Precision License Agreement [Member] | Maximum [Member] |  |  |  |  |  |  |  |  |  |  |
Investment Purchased Balance Shares (in shares) |  |  |  |  |  | 201,504 |  |  |  |  |
Strategic Platform License Agreement with MaxCyte, Inc. [Member] |  |  |  |  |  |  |  |  |  |  |
License Agreement, Amount Paid Upfront |  | $ 1,000 |  |  |  |  |  |  |  |  |
License Agreement, Additional Milestone Payments |  | 13,000 |  |  |  |  |  |  |  |  |
Licensing Agreement, Annual License Fee |  | $ 200 |  |  |  |  |  |  |  |  |
License Agreement, Term (Year) |  | 10 years |  |  |  |  |  |  |  |  |
License Agreement, Renewal Term (Year) |  | 5 years |  |  |  |  |  |  |  |  |
License Agreement, Written Notice Period (Day) |  | 90 days |  |  |  |  |  |  |  |  |

X
- Definition Reflects potential milestone payments to be received upon achievement of pre-specified milestone. + References No definition available. + Details
Name: | tgtx_AdditionalAmountReceivableOnAchievementOfPrespecifiedMilestones
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Represents investment purchased balance in shares. + References No definition available. + Details
Name: | tgtx_InvestmentPurchasedBalanceShares
Namespace Prefix: | tgtx_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents additional milestone payments for license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementAdditionalMilestonePayments
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the amount paid upfront for a license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementAmountPaidUpfront
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The cash portion of the amount paid upfront for license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementAmountPaidUpfrontCash
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The equity investment portion of the amount paid upfront for license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementAmountPaidUpfrontEquityInvestment
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents the deferred payment for license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementDeferredPayment
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Percentage of weighted average share price on payment under license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementPaymentPercentageOfWeightedAverageSharePrice
Namespace Prefix: | tgtx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Percentage of premium on equity investment under license agreement + References No definition available. + Details
Name: | tgtx_LicenseAgreementPercentageOfPremiumOnEquityInvestment
Namespace Prefix: | tgtx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Renewal term of license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementRenewalTerm
Namespace Prefix: | tgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of trading days for share price under license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementSharePriceTradingDays
Namespace Prefix: | tgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Term of the license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementTerm
Namespace Prefix: | tgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period for written notice under license agreement. + References No definition available. + Details
Name: | tgtx_LicenseAgreementWrittenNoticePeriod
Namespace Prefix: | tgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of expenses incurred under the license and collaboration agreement. + References No definition available. + Details
Name: | tgtx_LicenseAndCollaborationAgreementExpensesIncurred
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of a one-time, non-refundable payment made in accordance with commercialization agreements. + References No definition available. + Details
Name: | tgtx_LicenseAndCollaborationAgreementsOnetimeNonrefundablePayment
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of annual license fee under licensing agreement. + References No definition available. + Details
Name: | tgtx_LicensingAgreementAnnualLicenseFee
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Represents product sales, net related to performance obligations. + References No definition available. + Details
Name: | tgtx_ProductSalesNetRelatedToPerformanceObligations
Namespace Prefix: | tgtx_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty percentage on net product sales. + References No definition available. + Details
Name: | tgtx_RoyaltyPercentageOnNetProductSales
Namespace Prefix: | tgtx_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the term after the first commercial sale. + References No definition available. + Details
Name: | tgtx_TermAfterFirstCommercialSale
Namespace Prefix: | tgtx_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(15)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_AccountsPayableCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477802/946-310-45-1 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(5)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479196/954-310-45-1 Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Useful life of finite-lived intangible asset, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-5 + Details
Name: | us-gaap_FiniteLivedIntangibleAssetUsefulLife
Namespace Prefix: | us-gaap_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7 Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3 Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 815 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28 Reference 18: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14 Reference 19: http://www.xbrl.org/2003/role/exampleRef -Topic 944 -SubTopic 605 -Name Accounting Standards Codification -Section 55 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11 Reference 20: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1 Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A Reference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B Reference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=tgtx_PrecisionBiosciencesIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tgtx_LFBLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tgtx_CommercializationAgreementWithNeuraxpharmMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tgtx_BriumviUblituximabMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tgtx_PrecisionLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=tgtx_StrategicPlatformLicenseAgreementWithMaxcyteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |